Forte Biosciences, Inc.
No SEC Form 4 filings for $FBRX in the last 30 days.
See all $FBRX insider activity →Forte Biosciences (FBRX) reported Q2 2026 net loss of $23.33M and first-half 2026 net loss of $45.47M, both larger than prior-year periods. Basic loss per share from continuing operations narrowed to $2.18 from $2.32. The article also cites a $77/share cash tender offer tied to an argenx sale and a Simply Wall St fair value estimate of $73.8.
Forte Biosciences (FBRX) is scheduled to report Q2 earnings Aug. 17, with analysts expecting a loss of $1.01 per share on zero revenue. The company is being acquired by argenx for $77 per share in cash, with the tender offer set to expire Aug. 26. Deal progress and cash/clinical updates are key for investors.
Forte Biosciences (FBRX) reported Q2 2026 results on Aug. 12. It posted EPS of -$0.97, missing the -$0.90 estimate by $0.07. Revenue was $0, matching estimates. The article also cites institutional activity, including BlackRock adding shares and Point72 reducing holdings.
Over the past 7 days, alphai's AI scored 5 news stories mentioning FBRX (Forte Biosciences, Inc.). Coverage has been balanced: 2 bullish, 1 neutral, and 2 bearish.
Recent FBRX coverage spans mergers & acquisitions, earnings and financial news.
The print reinforces cash-burn risk while per-share losses improve slightly, keeping deal-execution and funding certainty central to the stock.
Near-term trading is driven less by standalone fundamentals and more by deal-close risk, cash position updates, and any program commentary ahead of the tender deadline.
The earnings miss and $0 revenue print are likely to pressure near-term sentiment and raise questions about operating viability and cash burn.
The $77 cash offer and tender start create a near-term takeover arbitrage and execution-risk window for FBRX holders.
The stock is effectively capped at the offer price, with upside mainly tied to deal certainty and any topping bid; downside is deal-failure risk.
alphai scores every news story that mentions FBRX with an AI model for sentiment and relevance, and aggregates insider trades from Forte Biosciences, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Forte Biosciences (FBRX) reported Q2 2026 net loss of $23.33M and first-half 2026 net loss of $45.47M, both larger than prior-year periods. Basic loss per share from continuing operations narrowed to $2.18 from $2.32. The article also cites a $77/share cash tender offer tied to an argenx sale and a Simply Wall St fair value estimate of $73.8.
4 min readForte Biosciences (FBRX) is scheduled to report Q2 earnings Aug. 17, with analysts expecting a loss of $1.01 per share on zero revenue. The company is being acquired by argenx for $77 per share in cash, with the tender offer set to expire Aug. 26. Deal progress and cash/clinical updates are key for investors.
6 min readForte Biosciences (FBRX) reported Q2 2026 results on Aug. 12. It posted EPS of -$0.97, missing the -$0.90 estimate by $0.07. Revenue was $0, matching estimates. The article also cites institutional activity, including BlackRock adding shares and Point72 reducing holdings.
2 min readForte Biosciences (FBRX) reported a $45.5 million net loss for the six months ended June 30, 2026, up from $26.9 million a year earlier, citing higher FB102 clinical and manufacturing spending. Cash and investments totaled $198.5 million after a $172.5 million April 2026 equity offering. Forte agreed to be acquired by argenx via a $77-per-share cash tender offer and merger.
6 min readArgenx SE (ARGX) agreed to buy Forte Biosciences (FBRX) for about $2.2 billion in cash, offering $77 per share, a ~40% premium to Forte’s prior close. The deal includes Forte’s FB102 anti-CD122 antibody and is expected to close in Q3 2026, pending approvals. Both boards approved.
6 min readargenx (ARGX) said its subsidiary Avena Merger Sub has started a tender offer to buy all outstanding Forte Biosciences (FBRX) shares for $77.00 per share in cash, net to the seller, under a July 26, 2026 merger agreement. The offer expires Aug. 26, 2026 unless extended, and Forte’s board recommends acceptance.
5 min readBiotech Growth Trust plc said it will benefit from Argenx SE’s $2.2 billion cash takeover of Forte Biosciences. Argenx offered $77 per share, a 40.5% premium. Forte was about 3% of Biotech Growth’s portfolio. The deal is expected to add about 1.2% to net asset value, after Biotech Growth’s November 2024 entry at $5.55 per share.
3 min readForte Biosciences (Nasdaq: FBRX) is being acquired by argenx SE in an all-cash deal valued at about $2.2 billion, or $77.00 per share, announced July 27, 2026, with expected Q3 2026 closing. The offer follows FB102 Phase Ib results in vitiligo and celiac disease, and includes FDA Fast Track for celiac. Forte raised $172.5M in April 2026.
6 min readArgenx (ARGX) said it will acquire Forte Biosciences (FBRX) for $77 per share, announced July 27. The article says FBRX began unusual price movement on June 29, weeks before the deal, and notes similar trading activity in ARGX. It cites company valuations of about $1.06 billion for FBRX and $54.57 billion for ARGX.
6 min readThe article discusses Argenx’s $2.2 billion bet via a deal with Forte Biosciences, focused on Forte’s FB102 anti-CD122 antibody for autoimmune diseases including celiac, vitiligo, and alopecia areata. It notes early celiac data and expected clinical readouts later in the year, while citing share pressure from an equity raise and delayed vitiligo timing.
3 min read
